Semaglutide · Chronic weight management

Clara reads your BMI trend, your comorbidities, and your tolerance before dosing Wegovy.

Clara reads your weight trajectory, your weight-related comorbidities, your medication list, and your prior GLP-1 history before drafting a starting dose. A physician signs off on every Rx.

Get started How it works

Weight management · 16 weeks on Wegovy

Needs review

Weight (current)218 lb −14 lb from baseline

BMI31.5 obesity class I

Current doseWegovy 1 mg weekly unchanged 4 weeks

Home BP128/82 down from 138/88

Clara: You've lost 6% of body weight in 16 weeks on Wegovy 1 mg, with tolerable side effects. Per the titration schedule, I'll draft a step up to 1.7 mg with a 4-week tolerance check for our physician to review.

Values and scenarios shown are illustrative examples only. All clinical assessments are individualized and reviewed by a licensed physician.

How it works

Connect your records. Clara reads the full picture. A physician signs off on every clinical action.

Connect your records

Clara auto-syncs your medical records from 150,000+ doctors' offices, hospitals, labs, and pharmacies: every prior lab, every prescription, every diagnosis. Wearable data syncs automatically on Standard and Concierge plans. Free to start, no credit card.

Clara checks candidacy, interactions, and dose

Before drafting any prescription, Clara reads your full chart: indication, contraindications, every drug and supplement on your list, and any prior trials of this medication. The interaction check runs against the full FDA label — not just the common flagged pairs.

Physician-reviewed Rx, then on-clock monitoring

Every prescription is reviewed and signed off by a licensed physician before it reaches your pharmacy. Clara then tracks the key monitoring labs on schedule — not at your next annual visit — and flags when dose adjustment or follow-up is warranted.

About semaglutide

Semaglutide: what it treats, who it's for, and what Clara reads before prescribing.

FDA-approved indications

✓Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity

✓Reduction of risk of major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight

✓Chronic weight management in pediatric patients aged 12 years and older with obesity (BMI ≥95th percentile for age and sex)

Who Clara evaluates for semaglutide

✓Adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

✓Adults with established cardiovascular disease and either obesity or overweight, where MACE risk reduction is a goal

✓Patients already on a stable Wegovy regimen who need dose review, refills, and on-schedule tolerance monitoring

✗Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

What Clara checks

Four things Clara reads before drafting — and keeps reading after.

🎯

Indication and candidacy

Clara reads your BMI history, your weight-related comorbidities (hypertension, diabetes, dyslipidemia, sleep apnea), your prior weight-management interventions, and your CV history before confirming Wegovy candidacy. It cross-checks your personal and family history for medullary thyroid carcinoma or MEN 2 syndrome — both contraindications — before drafting.

⚠️

Drug and supplement interactions

Wegovy delays gastric emptying and can alter absorption of co-administered oral medications. Co-administration with insulin or sulfonylureas in patients with type 2 diabetes increases the risk of hypoglycemia, often requiring a dose reduction. Concomitant use with other GLP-1 receptor agonists is not recommended. Clara reads your full medication list before drafting.

⚖️

Dose sizing

Per the Wegovy prescribing information, the standard escalation is 0.25 mg weekly × 4 weeks, then 0.5 mg × 4 weeks, then 1 mg × 4 weeks, then 1.7 mg × 4 weeks, then 2.4 mg weekly maintenance. Each step is for tolerability rather than weight effect; Clara watches your side-effect log against the calendar.¹

📅

On-schedule monitoring

Clara prompts a weight and BP recheck at 1 month and 3 months after initiation, then every 3 months. Renal function is monitored during dose escalation and with volume-depletion symptoms. Patients with established CV disease have lipid and CV risk re-evaluation on schedule.

Important safety information

Semaglutide (Wegovy) is a prescription medication. The following is a summary of key safety information from the FDA-approved prescribing information. This is not a complete list — see the full prescribing information linked in the footer.

Boxed warning

In rodent studies, semaglutide caused thyroid C-cell tumors. It is unknown whether Wegovy causes such tumors in humans. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Warnings

Acute pancreatitis (discontinue if suspected). Acute kidney injury (especially with dehydration from GI side effects). Hypoglycemia when used with insulin or sulfonylureas in patients with T2D. Acute gallbladder disease. Increased heart rate. Suicidal behavior and ideation (monitor for new or worsening mood changes). Hypersensitivity reactions. Most common adverse reactions are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue.

Monitoring requirements

Weight, BMI, and blood pressure at baseline and at scheduled follow-up intervals. Renal function during dose escalation and with volume-depletion symptoms. Heart rate (Wegovy can cause modest resting-HR increases). Mental-health check-ins for emergence of depression or suicidal ideation.

Special populations

Pregnancy: Wegovy is contraindicated in pregnancy due to potential fetal harm; discontinue 2 months before a planned pregnancy. Lactation: not recommended (limited data). Pediatric: approved for chronic weight management in patients 12 years and older with obesity (BMI ≥95th percentile). Geriatric: no overall dose adjustment, increased monitoring is reasonable. Renal/hepatic impairment: no dose adjustment recommended.

Why Clara

How Clara manages Wegovy differently.

	Clara	Cash-pay DTC weight-loss telehealth	General telehealth	Your doctor
Cost to start	Free (records + chat)	Subscription required	Per-visit fee	$150+ copay
Monthly cost	From $25/mo · Standard $50/mo · HSA/FSA eligible	$199–$299/mo bundled cash-pay	Per-visit, varies	Per-visit copay
Reads full chart before prescribing	✓ Auto-synced, 150,000+ sources	Intake questionnaire only	Self-uploaded only	Within a single practice
Prescribes FDA-approved branded medication (not compounded)	✓ Branded Wegovy	Often compounded semaglutide	Varies	✓
Prescription may be covered by your insurance	✓	Cash-pay bundled	Varies	✓
On-schedule weight, BP, and tolerance monitoring	✓ Continuous review	Patient-initiated	Patient-initiated	At next visit
Biomarker panel included	✓ 74–108 tests in membership	Extra cost	Extra cost	Per-test copay
Full primary care (beyond weight)	✓	Single-vertical	Single-condition	✓

The AI difference

What an AI that reads your full chart makes possible in primary care.

A clinician in a 15-minute visit reads the last panel. Clara reads every result you've ever had drawn — every lab, every wearable reading, every medication change — and cross-references them in a single pass. That's not a time-management difference. It's a category-of-work difference. The AI handles the data; licensed physicians handle every clinical decision.

Reads your entire chart, every time

Clara auto-syncs from 150,000+ medical sources and reads every prior result, medication, and diagnosis together — not just the last visit's notes. Pattern-finding across years of data is what the AI is built for.

Continuous monitoring, not annual snapshots

Clara watches for drift between visits — a creeping lab value, a wearable trend, a new medication interaction — and surfaces it when it's actionable, not when you happen to schedule an appointment.

Physician review on every clinical action

Clara drafts; physicians decide. Every prescription and lab order is reviewed and signed by a licensed clinician before it reaches your pharmacy or lab. The AI handles intake, reasoning, and follow-up. The physician handles sign-off.

Common questions

Semaglutide with Clara: questions patients ask.

What does Clara cost?

Connecting your medical records and chatting with Clara is free. To access physician-reviewed prescriptions and lab orders, plans start at $50/month. Standard ($50/mo) includes 74 biomarker tests, wearable integration, and weekly record sync. Concierge ($150/mo) includes 108 biomarker tests and expanded panels. All plans are HSA/FSA eligible. Biomarker panels are included in the membership — not billed separately and not billed to insurance. Medications and ad-hoc lab orders are billed by your pharmacy or lab and may be covered by your insurance.

Can I use my insurance, HSA, or FSA?

Clara's membership is cash-pay and not billed through insurance, but every plan is HSA/FSA eligible. Prescriptions Clara's physicians write go to your pharmacy and may be covered by your plan like any other script — Clara prescribes FDA-approved branded and generic medications, not compounded formulations. Ad-hoc lab orders may also be covered by your insurance when applicable.

Is Clara a real medical practice?

Yes. Clara operates through affiliated professional corporations licensed in all 50 states. All diagnoses, prescriptions, and lab orders are reviewed and signed off by licensed physicians. Clara's AI handles intake, continuous monitoring, and clinical reasoning — the physician sign-off happens before any clinical action reaches you.

How is this different from my regular doctor?

A 15-minute annual visit can review your most recent results. Clara reads every lab you've had drawn, every medication you've been on, and every wearable data point in a single pass — and does it every time you interact, not just at annual visits. Your PCP remains the right choice for in-person exams, procedures, and anything Clara refers out. Clara fills the continuous monitoring gap between visits.

Is my data private?

Clara is HIPAA compliant. Your medical records and wearable data are used solely to personalize your care. They are not sold to third parties and are not used to train public AI models.

What's the difference between Wegovy and Ozempic?

Both are semaglutide, the same molecule, made by Novo Nordisk. Wegovy is FDA-approved for chronic weight management (and for MACE risk reduction in people with established CVD and obesity or overweight); Ozempic is FDA-approved for type 2 diabetes. Different indications, different dose strengths at the upper end, different insurance coverage rules. Clara reviews your diagnoses and prescribes the on-label brand for your situation.

Does Clara prescribe branded Wegovy or compounded semaglutide?

Clara's physicians prescribe FDA-approved branded Wegovy, not compounded semaglutide. Branded Wegovy goes through the standard pharmacy fill and may be covered by your insurance. Compounded semaglutide is a cash-pay product sold by some telehealth brands; Clara does not use it because the FDA has issued safety concerns about compounded GLP-1 formulations and because branded coverage through insurance is better long-term economics for most patients.

How long do I stay on Wegovy?

Wegovy is intended for long-term chronic weight management. Stopping Wegovy is generally associated with regaining lost weight over time. Clara monitors your weight, BP, BMI, and tolerance throughout, and your physician reviews continuation, dose adjustments, or off-ramps at every visit. Some patients taper or discontinue once a weight-related comorbidity has resolved; this is an individualized decision.